Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Sep 28, 2020
Two-Year Data of Evrysdi™ (risdiplam) in Infants with Spinal Muscular Atrophy Demonstrate Continued Improvement of Developmental Milestones
- Patients in Part 1 of the FIREFISH study demonstrated gains in motor milestones between months 12 and 24 -   - Strong Evrysdi™ launch following approval with broad label - SOUTH PLAINFIELD, N.J. , Sept. 28, 2020 /PRNewswire/ --  PTC Therapeutics, Inc.
Additional Formats
Sep 25, 2020
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , Sept. 25, 2020 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on September 21, 2020 it approved non-statutory stock options to purchase an aggregate of 75,670 shares of its common stock and 12,845 restricted stock units ("RSUs"), each
Additional Formats
Sep 24, 2020
PTC Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit
SOUTH PLAINFIELD, N.J. , Sept. 24, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 1 st at 9:00 a.m. ET .
Additional Formats
Sep 09, 2020
PTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program for Individuals Suspected of Having Neurotransmitter Disorders
- Early diagnosis through genetic testing may lead to improved long-term outcomes for patients with neurotransmitter disorders, including AADC deficiency - SOUTH PLAINFIELD, N.J. , Sept. 9, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new program that provides
Additional Formats
Sep 08, 2020
PTC Therapeutics' 2020 STRIVE Awards for Duchenne Muscular Dystrophy Recognize Four Patient Advocacy Organizations
- Advocacy organizations in Argentina, Hungary, Russia and the U.S awarded funding -   - Total of 32 projects have been awarded funding since Awards inception in 2015 - SOUTH PLAINFIELD, N.J. , Sept. 8, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the winners of its
Additional Formats
Sep 03, 2020
PTC Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
SOUTH PLAINFIELD, N.J. , Sept. 3, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Cantor Virtual Global Healthcare Conference on Thursday, September 17 th at 9:20 a.m. ET .
Additional Formats
Aug 26, 2020
PTC Therapeutics Announces First Commercial Milestone Payment Following U.S. FDA Approval of Evrysdi™ (risdiplam)
SOUTH PLAINFIELD, N.J. , Aug. 26, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company achieved a $20 million milestone payment from Roche under its License and Collaboration Agreement. The milestone payment was triggered by the first commercial sale of
Additional Formats
Aug 21, 2020
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , Aug. 21, 2020 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on August 18, 2020 it approved non-statutory stock options to purchase an aggregate of 49,165 shares of its common stock and 14,175 restricted stock units ("RSUs"), each representing
Additional Formats
Aug 17, 2020
PTC Announces the Acceptance of the European Marketing Authorization Application for Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy
- Marketing Authorization Application (MAA) based on data from multiple pivotal trials in infants, children and adult patients with SMA -   - Milestone triggers $15M payment from Roche - SOUTH PLAINFIELD, N.J. , Aug. 17, 2020 /PRNewswire/ --  PTC Therapeutics, Inc.
Additional Formats
Aug 07, 2020
PTC Therapeutics Announces FDA Approval of Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy in Adults and Children 2 Months and Older
- Evrysdi represents the first at home, oral treatment approved for infants, children and adults with all SMA types-   - Marketing Authorization Application submission to European Medicines Agency is imminent -   - Risdiplam is the first approved therapy discovered and developed from PTC
Additional Formats